Stay updated on Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Sign up to get notified when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.

Latest updates to the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page
- CheckyesterdayChange DetectedThe page footer was updated to reflect a new site revision number, moving from v3.5.2 to v3.5.3. This represents an update to the ClinicalTrials.gov page software version rather than any change to the clinical trial details.SummaryDifference0.0%

- Check9 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2. This appears to be a minor version bump with no changes to study content or interactions.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check37 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check51 days agoChange DetectedRevision tag on the page updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check73 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2 in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check80 days agoChange DetectedRevision: v3.4.1 is now shown on the page, replacing the previous v3.4.0. This is a minor site update and does not modify any study details or eligibility criteria.SummaryDifference0.0%

Stay in the know with updates to Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.